Bereich
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial
Kreissl S, Keller U, Kühnhardt D, Ostermann H, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Diehl V, Dietlein M, Engert A, Borchmann P, Bentz M, Hitz F, Topp M, Goergen H, Buehnen I, Kobe C, Moccia A, Greil R, Eichenauer D, Zijlstra J, Markova J, Meissner J, Feuring-Buske M, Soekler M, Beck H, Willenbacher W, Ludwig W, Pabst T, German Hodgkin Study Group. PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial. Lancet Haematol 2021; 8:e398-e409.
01.06.2021PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial
01.06.2021Lancet Haematol 2021; 8:e398-e409
Kreissl Stefanie, Keller Ulrich Bernd, Kühnhardt Dagmar, Ostermann Helmut, Hertenstein Bernd, Aulitzky Walter, Maschmeyer Georg, Vieler Tom, Eich Hans, Baues Christian, Stein Harald, Fuchs Michael, Diehl Volker, Dietlein Markus, Engert Andreas, Borchmann Peter, Bentz Martin, Hitz Felicitas, Topp Max S, Goergen Helen, Buehnen Ina, Kobe Carsten, Moccia Alden, Greil Richard, Eichenauer Dennis A, Zijlstra Josée M, Markova Jana, Meissner Julia, Feuring-Buske Michaela, Soekler Martin, Beck Hans-Joachim, Willenbacher Wolfgang, Ludwig Wolf-Dieter, Pabst Thomas, German Hodgkin Study Group
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021
Thill M, Schmidt M, Rody A, Rhiem K, Reimer T, Park-Simon T, Nitz U, Mundhenke C, Maass N, Lux M, Schneeweiss A, Schütz F, Sinn H, Janni W, Müller V, Wöckel A, Witzel I, Untch M, Thomssen C, Stickeler E, Solomayer E, Solbach C, Luftner D, Loibl S, Dall P, Budach W, Blohmer J, Bauerfeind I, Banys-Paluchowski M, Albert U, Jackisch C, Friedrich M, Kolberg-Liedtke C, Fallenberg E, Fasching P, Fehm T, Kümmel S, Kühn T, Krug D, Kreipe H, Huober J, Heil J, Harbeck N, Gluz O, Gerber B, Ditsch N. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021. Breast Care (Basel) 2021; 16:214-227.
01.06.2021AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021
01.06.2021Breast Care (Basel) 2021; 16:214-227
Thill Marc, Schmidt Marcus, Rody Achim, Rhiem Kerstin, Reimer Toralf, Park-Simon Tjoung-Won, Nitz Ulrike, Mundhenke Christoph, Maass Nicolai, Lux Michael P, Schneeweiss Andreas, Schütz Florian, Sinn Hans-Peter, Janni Wolfgang, Müller Volkmar, Wöckel Achim, Witzel Isabell, Untch Michael, Thomssen Christoph, Stickeler Elmar, Solomayer Erich-Franz, Solbach Christine, Luftner Diana, Loibl Sibylle, Dall Peter, Budach Wilfried, Blohmer Jens-Uwe, Bauerfeind Ingo, Banys-Paluchowski Maggie, Albert Ute-Susann, Jackisch Christian, Friedrich Michael, Kolberg-Liedtke Cornelia, Fallenberg Eva M, Fasching Peter A, Fehm Tanja, Kümmel Sherko, Kühn Thorsten, Krug David, Kreipe Hans-Heinrich, Huober Jens, Heil Jörg, Harbeck Nadia, Gluz Oleg, Gerber Bernd, Ditsch Nina
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021
Ditsch N, Schmidt M, Rody A, Rhiem K, Reimer T, Park-Simon T, Nitz U, Mundhenke C, Maass N, Lux M, Schneeweiss A, Schütz F, Sinn H, Janni W, Müller V, Wöckel A, Witzel I, Untch M, Thomssen C, Stickeler E, Solomayer E, Solbach C, Luftner D, Loibl S, Fallenberg E, Dall P, Budach W, Blohmer J, Bauerfeind I, Banys-Paluchowski M, Albert U, Kolberg-Liedtke C, Friedrich M, Fasching P, Fehm T, Gerber B, Kümmel S, Kühn T, Krug D, Kreipe H, Jackisch C, Huober J, Heil J, Harbeck N, Gluz O, Thill M. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021. Breast Care (Basel) 2021; 16:228-235.
27.05.2021AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021
27.05.2021Breast Care (Basel) 2021; 16:228-235
Ditsch Nina, Schmidt Marcus, Rody Achim, Rhiem Kerstin, Reimer Toralf, Park-Simon Tjoung-Won, Nitz Ulrike, Mundhenke Christoph, Maass Nicolai, Lux Michael P, Schneeweiss Andreas, Schütz Florian, Sinn Hans-Peter, Janni Wolfgang, Müller Volkmar, Wöckel Achim, Witzel Isabell, Untch Michael, Thomssen Christoph, Stickeler Elmar, Solomayer Erich-Franz, Solbach Christine, Luftner Diana, Loibl Sibylle, Fallenberg Eva M, Dall Peter, Budach Wilfried, Blohmer Jens-Uwe, Bauerfeind Ingo, Banys-Paluchowski Maggie, Albert Ute-Susann, Kolberg-Liedtke Cornelia, Friedrich Michael, Fasching Peter A, Fehm Tanja, Gerber Bernd, Kümmel Sherko, Kühn Thorsten, Krug David, Kreipe Hans-Heinrich, Jackisch Christian, Huober Jens, Heil Jörg, Harbeck Nadia, Gluz Oleg, Thill Marc
Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: German Expert Opinions on the 17th International St. Gallen Consensus Conference
Untch M, Harbeck N, Thill M, Schneeweiss A, Müller V, Luftner D, Loibl S, Kühn T, Krug D, Kolberg-Liedtke C, Janni W, Jackisch C, Huober J, Haidinger R, Denkert C, Budach W, Brucker S, Fasching P, Thomssen C. Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: German Expert Opinions on the 17th International St. Gallen Consensus Conference. Geburtshilfe Frauenheilkd 2021; 81:637-653.
19.05.2021Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: German Expert Opinions on the 17th International St. Gallen Consensus Conference
19.05.2021Geburtshilfe Frauenheilkd 2021; 81:637-653
Untch Michael, Harbeck Nadia, Thill Marc, Schneeweiss Andreas, Müller Volkmar, Luftner Diana, Loibl Sibylle, Kühn Thorsten, Krug David, Kolberg-Liedtke Cornelia, Janni Wolfgang, Jackisch Christian, Huober Jens, Haidinger Renate, Denkert Carsten, Budach Wilfried, Brucker Sara Y, Fasching Peter A, Thomssen Christoph
A case of reactive hemophagocytic lymphohistiocytosis
Lorenz L, Silzle T, Brühl D, Haller S, Babouee Flury B (2021). A case of reactive hemophagocytic lymphohistiocytosis - The value of asking the right questions at the right time.
19.05.2021A case of reactive hemophagocytic lymphohistiocytosis
19.05.2021SGAIM Frühjahrskongress
Lorenz Lisa, Silzle Tobias, Brühl Daniel, Haller Sabine, Babouee Flury Baharak
Computational Treatment Simulations to Assess the Need for Personalized Tamoxifen Dosing in Breast Cancer Patients of Different Biogeographical Groups
Mueller-Schoell A, Mikus G, Huisinga W, Jörger M, Schwab M, Mürdter T, van Dyk M, Klopp-Schulze L, Michelet R, Kloft C. Computational Treatment Simulations to Assess the Need for Personalized Tamoxifen Dosing in Breast Cancer Patients of Different Biogeographical Groups. Cancers (Basel) 2021; 13
18.05.2021Computational Treatment Simulations to Assess the Need for Personalized Tamoxifen Dosing in Breast Cancer Patients of Different Biogeographical Groups
18.05.2021Cancers (Basel) 2021; 13
Mueller-Schoell Anna, Mikus Gerd, Huisinga Wilhelm, Jörger Markus, Schwab Matthias, Mürdter Thomas E, van Dyk Madelé, Klopp-Schulze Lena, Michelet Robin, Kloft Charlotte
Fitness-to-drive for glioblastoma patients: Guidance from the Swiss Neuro-Oncology Society (SwissNOS) and the Swiss Society for Legal Medicine (SGRM)
Hofer S, Baumert B, Läubli H, Gramatzki D, Reinert M, Pesce G, Schucht P, Frank I, Lehnick D, Weiss T, Wirsching H, Wolpert F, Roth P, Eggenberger N, Pflugshaupt T, Keller K, Imbach L, Roelcke U, Hutter G, Hundsberger T, Hertler C, Le Rhun E, Vasella F, Cordier D, Neidert M, Hottinger A, Migliorini D, Weller M. Fitness-to-drive for glioblastoma patients: Guidance from the Swiss Neuro-Oncology Society (SwissNOS) and the Swiss Society for Legal Medicine (SGRM). Swiss Med Wkly 2021; 151:w20501.
16.05.2021Fitness-to-drive for glioblastoma patients: Guidance from the Swiss Neuro-Oncology Society (SwissNOS) and the Swiss Society for Legal Medicine (SGRM)
16.05.2021Swiss Med Wkly 2021; 151:w20501
Hofer Silvia, Baumert Brigitta, Läubli Heinz, Gramatzki Dorothee, Reinert Michael, Pesce Gianfranco, Schucht Philippe, Frank Irène, Lehnick Dirk, Weiss Tobias, Wirsching Hans-Georg, Wolpert Fabian, Roth Patrick, Eggenberger Noemi, Pflugshaupt Tobias, Keller Kristina, Imbach Lukas, Roelcke Ulrich, Hutter Gregor, Hundsberger Thomas, Hertler Caroline, Le Rhun Emilie, Vasella Flavio, Cordier Dominik, Neidert Marian Christoph, Hottinger Andreas, Migliorini Denis, Weller Michael
Two-year follow-up after a six-week high-intensity training intervention study with breast cancer patients: physiological, psychological and immunological differences
Schulz S, Steinacker J, Leinert E, Huober J, Janni W, Treff G, Kirsten J, Otto S, Schumann U, Bizjak D. Two-year follow-up after a six-week high-intensity training intervention study with breast cancer patients: physiological, psychological and immunological differences. Disabil Rehabil 2021:1-8.
11.05.2021Two-year follow-up after a six-week high-intensity training intervention study with breast cancer patients: physiological, psychological and immunological differences
11.05.2021Disabil Rehabil 2021:1-8
Schulz Sebastian V W, Steinacker Jürgen M, Leinert Elena, Huober Jens, Janni Wolfgang, Treff Gunnar, Kirsten Johannes, Otto Stephanie, Schumann Uwe, Bizjak Daniel A
Treatment of progressive multiple sclerosis with high-dose all-trans retinoic acid - no clear evidence of positive disease modifying effects
Ruschil C, Dubois E, Stefanou M, Kowarik M, Ziemann U, Schittenhelm M, Krumbholz M, Bischof F. Treatment of progressive multiple sclerosis with high-dose all-trans retinoic acid - no clear evidence of positive disease modifying effects. Neurol Res Pract 2021; 3:25.
10.05.2021Treatment of progressive multiple sclerosis with high-dose all-trans retinoic acid - no clear evidence of positive disease modifying effects
10.05.2021Neurol Res Pract 2021; 3:25
Ruschil Christoph, Dubois Evelyn, Stefanou Maria-Ioanna, Kowarik Markus Christian, Ziemann Ulf, Schittenhelm Marcus, Krumbholz Markus, Bischof Felix
Drug-Induced Pseudo-Central Serous Chorioretinopathy in Carcinoma Patients
Jung S, Valmaggia C, Jörger M, Todorova M. Drug-Induced Pseudo-Central Serous Chorioretinopathy in Carcinoma Patients. Klin Monbl Augenheilkd 2021; 238:403-409.
30.04.2021Drug-Induced Pseudo-Central Serous Chorioretinopathy in Carcinoma Patients
30.04.2021Klin Monbl Augenheilkd 2021; 238:403-409
Jung Sascha, Valmaggia Christophe, Jörger Markus, Todorova Margarita
Drug-Induced Pseudo-Central Serous Chorioretinopathy in Carcinoma Patients
Jung S, Valmaggia C, Jörger M, Todorova M. Drug-Induced Pseudo-Central Serous Chorioretinopathy in Carcinoma Patients. Klin Monbl Augenheilkd 2021; 238:403-409.
30.04.2021Drug-Induced Pseudo-Central Serous Chorioretinopathy in Carcinoma Patients
30.04.2021Klin Monbl Augenheilkd 2021; 238:403-409
Jung Sascha, Valmaggia Christophe, Jörger Markus, Todorova Margarita
[Home infusion therapy for Pompe disease: Recommendations for German-speaking countries]
Hahn A, Schlegel T, Ballhausen D, Lagler F, Ziegler A, Wenninger S, Löscher W, Hundsberger T, Boentert M, Lampe C, Schoser B. [Home infusion therapy for Pompe disease: Recommendations for German-speaking countries]. Fortschr Neurol Psychiatr 2021
27.04.2021[Home infusion therapy for Pompe disease: Recommendations for German-speaking countries]
27.04.2021Fortschr Neurol Psychiatr 2021
Hahn Andreas, Schlegel Thomas, Ballhausen Diana, Lagler Florian, Ziegler Andreas, Wenninger Stephan, Löscher Wolfgang, Hundsberger Thomas, Boentert Matthias, Lampe Christina, Schoser Benedikt
Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial
Froesch P, Früh M, Gautschi O, Sessa C, König D, Metaxas Y, Colombo I, Schmid S, Oppliger Leibundgut E, Rusterholz C, Godar G, Li Q, Rothschild S, Mark M, Swiss Group for Clinical Cancer Research (SAKK). Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial. Lung Cancer 2021; 156:91-99.
25.04.2021Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial
25.04.2021Lung Cancer 2021; 156:91-99
Froesch Patrizia, Früh Martin, Gautschi Oliver, Sessa Cristiana, König David, Metaxas Yannis, Colombo Ilaria, Schmid Sabine, Oppliger Leibundgut Elisabeth, Rusterholz Corinne, Godar Gilles, Li Qiyu, Rothschild Sacha I, Mark Michael, Swiss Group for Clinical Cancer Research (SAKK)
In Reply
Rugo H, Huober J, García-Sáenz J, Masuda N, Sohn J, Andre V, Barriga S, Cox J, Goetz M. In Reply. Oncologist 2021; 26:e1286-e1287.
19.04.2021In Reply
19.04.2021Oncologist 2021; 26:e1286-e1287
Rugo Hope S, Huober Jens, García-Sáenz José A, Masuda Norikazu, Sohn Joo Hyuk, Andre Valerie A M, Barriga Susana, Cox Joanne, Goetz Matthew
SalvGlandDx - a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets.
Freiberger S, Brada M, Fritz C, Höller S, Vogetseder A, Horcic M, Bihl M, Michal M, Lanzer M, Wartenberg M, Borner U, Bode P, Broglie M, Rordorf T, Morand G, Rupp N. SalvGlandDx - a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets. Neoplasia 2021; 23:473-487.
18.04.2021SalvGlandDx - a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets.
18.04.2021Neoplasia 2021; 23:473-487
Freiberger Sandra N, Brada Muriel, Fritz Christine, Höller Sylvia, Vogetseder Alexander, Horcic Milo, Bihl Michel, Michal Michal, Lanzer Martin, Wartenberg Martin, Borner Urs, Bode Peter K, Broglie Martina A, Rordorf Tamara, Morand Grégoire B, Rupp Niels J
LC3A positive "stone like structures" are differentially associated with survival outcomes and CD68 macrophage infiltration in patients with lung adenocarcinoma and squamous cell carcinoma.
Gachechiladze M, Überall I, Skanderová D, Matchavariani J, Ibrahim M, Shani I, Smičková P, Kolek V, Cierna L, Kleine-Tebbe J, Stahel R, Joerger M, Soltermann A, Škarda J. LC3A positive "stone like structures" are differentially associated with survival outcomes and CD68 macrophage infiltration in patients with lung adenocarcinoma and squamous cell carcinoma. Lung Cancer 2021; 156:129-135.
15.04.2021LC3A positive "stone like structures" are differentially associated with survival outcomes and CD68 macrophage infiltration in patients with lung adenocarcinoma and squamous cell carcinoma.
15.04.2021Lung Cancer 2021; 156:129-135
Gachechiladze Mariam, Überall Ivo, Skanderová Daniela, Matchavariani J, Ibrahim M, Shani Ilay, Smičková Petra, Kolek Vítězslav, Cierna L, Kleine-Tebbe Jörg, Stahel R, Joerger M, Soltermann A, Škarda Josef
Tumour neoantigen mimicry by microbial species in cancer immunotherapy
Bösch M, Baty F, Rothschild S, Tamm M, Jörger M, Früh M, Brutsche M. Tumour neoantigen mimicry by microbial species in cancer immunotherapy. Br J Cancer 2021; 125:313-323.
06.04.2021Tumour neoantigen mimicry by microbial species in cancer immunotherapy
06.04.2021Br J Cancer 2021; 125:313-323
Bösch Maximilian, Baty Florent, Rothschild Sacha I, Tamm Michael, Jörger Markus, Früh Martin, Brutsche Martin
Pembrolizumab-Associated CD8 Vasculitic Mononeuritis Multiplex in a Patient With Mesothelioma
Baldauf M, Jörger M, Flatz L, Rodriguez R, Frank S, Felbecker A, Hundsberger T. Pembrolizumab-Associated CD8 Vasculitic Mononeuritis Multiplex in a Patient With Mesothelioma. Neurol Neuroimmunol Neuroinflamm 2021; 8
06.04.2021Pembrolizumab-Associated CD8 Vasculitic Mononeuritis Multiplex in a Patient With Mesothelioma
06.04.2021Neurol Neuroimmunol Neuroinflamm 2021; 8
Baldauf Michaela, Jörger Markus, Flatz Lukas, Rodriguez Regulo, Frank Stephan, Felbecker Ansgar, Hundsberger Thomas
Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study
Johnson M, Rich P, Hung J, Appenzeller C, Sun Z, Maag D, Luo Y, Nickner C, Vajikova A, Komarnitsky P, van der Leest C, Okamoto I, Zvirbule Z, Laktionov K, Helland A, Cho B, Gutierrez V, Colinet B, Lena H, Wolf M, Gottfried M, Bar J. Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study. J Thorac Oncol 2021; 16:1570-1581.
03.04.2021Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study
03.04.2021J Thorac Oncol 2021; 16:1570-1581
Johnson Melissa L, Rich Patricia, Hung Jen-Yu, Appenzeller Christina, Sun Zhaowen, Maag David, Luo Yan, Nickner Caroline, Vajikova Alena, Komarnitsky Philip, van der Leest Cor, Okamoto Isamu, Zvirbule Zanete, Laktionov Konstantin, Helland Aslaug, Cho Byoung Chul, Gutierrez Vanesa, Colinet Benoît, Lena Herve, Wolf Martin, Gottfried Maya, Bar Jair
Radiotherapy for thymic epithelial tumours: a review
Süveg K, Putora P, Jörger M, Iseli T, Fischer G, Ammann K, Glatzer M. Radiotherapy for thymic epithelial tumours: a review. Transl Lung Cancer Res 2021; 10:2088-2100.
01.04.2021Radiotherapy for thymic epithelial tumours: a review
01.04.2021Transl Lung Cancer Res 2021; 10:2088-2100
Süveg Krisztian, Putora Paul Martin, Jörger Markus, Iseli Thomas, Fischer Galina Farina, Ammann Karlheinz, Glatzer Markus